Prioritizing metastatic non-small cell lung cancer launch and focusing research and development activities in areas of greatest anticipated value creation
Expected reduction in residual operating expenses of approximately $60 million, including a reduction in headcount of approximately 200 colleagues, 13% of total workforce
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.